In FLT3 mutated AML, combining venetoclax plus FLT3 inhibitors such as quizartinib or gilteritinib with or without hypomethylating agents also induced impressive response rates in R/R AML patients [42, 43]. This evidence concerns the gene FLT3 and acute myeloid leukemia.